Literature DB >> 35149138

Impact of serotonergic medication on interoception in major depressive disorder.

Kaiping Burrows1, Danielle C DeVille2, Kelly T Cosgrove2, Rayus T Kuplicki2, Martin P Paulus3, Robin Aupperle3, Sahib S Khalsa3, Jennifer L Stewart3.   

Abstract

Unmedicated individuals with major depressive disorder (MDD) show abnormal interoception, but it is unclear whether antidepressant treatment via serotonergic medication alters this relationship. The current cross-sectional study examined associations between neural and behavioral indices of interoceptive processing and chronic serotonergic medication administration in MDD. 47 selective serotonin reuptake inhibitor (SSRI)-medicated MDD (MDD-SSRI) individuals were propensity-matched with 48 unmedicated current MDD (MDD-UnMed) and 41 healthy comparison (HC) participants on demographics including age, sex, body mass index, education, as well as on dimensional scales of symptom severity including depression and anxiety. All participants completed an interoceptive attention task during functional magnetic resonance imaging, and a behavioral heartbeat tapping task under three conditions: Guessing, No Guessing, and Breath Hold. Relative to HC, both MDD groups: (1) exhibited lower mid-insula, amygdala, putamen, and caudate activation during interoceptive versus exteroceptive attention; and (2) showed poorer heartbeat tapping performance during the Breath Hold condition. However, the MDD-SSRI group reported higher intensity ratings of heartbeat and stomach sensations than MDD-UnMed and HC during the interoceptive attention task. These findings suggest that the attenuated patterns of neural activation observed in depressed individuals during interoceptive attention are not ameliorated by the chronic administration of serotonergic medications. However, amplified interoceptive sensation ratings suggest a potential impact of chronic serotonergic medication on conscious experiences of internal body states. Future investigations will need to determine the extent to which serotonergic medications acutely influence interoceptive processing, and whether such changes play a role in therapeutic responses during treatment initiation.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Functional Megnetic Resonance ImagingMajor depressive disorder; Insula; Interoception; Selective serotonin reuptake inhibitor

Mesh:

Year:  2022        PMID: 35149138      PMCID: PMC8958795          DOI: 10.1016/j.biopsycho.2022.108286

Source DB:  PubMed          Journal:  Biol Psychol        ISSN: 0301-0511            Impact factor:   3.251


  60 in total

1.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

2.  Dual task performance of working memory and postural control in major depressive disorder.

Authors:  Michail Doumas; Caroline Smolders; Els Brunfaut; Filip Bouckaert; Ralf T H Krampe
Journal:  Neuropsychology       Date:  2011-11-07       Impact factor: 3.295

3.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.

Authors:  David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays
Journal:  J Clin Epidemiol       Date:  2010-08-04       Impact factor: 6.437

4.  Major depressive disorder is associated with abnormal interoceptive activity and functional connectivity in the insula.

Authors:  Jason A Avery; Wayne C Drevets; Scott E Moseman; Jerzy Bodurka; Joel C Barcalow; W Kyle Simmons
Journal:  Biol Psychiatry       Date:  2013-12-08       Impact factor: 13.382

5.  Diminished responses to bodily threat and blunted interoception in suicide attempters.

Authors:  Danielle C DeVille; Rayus Kuplicki; Jennifer L Stewart; Martin P Paulus; Sahib S Khalsa
Journal:  Elife       Date:  2020-04-07       Impact factor: 8.140

6.  Explanatory models for psychiatric illness.

Authors:  Kenneth S Kendler
Journal:  Am J Psychiatry       Date:  2008-05-15       Impact factor: 18.112

7.  Respiration pattern variability and related default mode network connectivity are altered in remitted depression.

Authors:  Vera Eva Zamoscik; Stephanie Nicole Lyn Schmidt; Martin Fungisai Gerchen; Christos Samsouris; Christina Timm; Christine Kuehner; Peter Kirsch
Journal:  Psychol Med       Date:  2018-01-16       Impact factor: 7.723

Review 8.  Active interoceptive inference and the emotional brain.

Authors:  Anil K Seth; Karl J Friston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-10-10       Impact factor: 6.237

9.  Predicting the naturalistic course of depression from a wide range of clinical, psychological, and biological data: a machine learning approach.

Authors:  Richard Dinga; Andre F Marquand; Dick J Veltman; Aartjan T F Beekman; Robert A Schoevers; Albert M van Hemert; Brenda W J H Penninx; Lianne Schmaal
Journal:  Transl Psychiatry       Date:  2018-11-05       Impact factor: 6.222

10.  Disrupted Dorsal Mid-Insula Activation During Interoception Across Psychiatric Disorders.

Authors:  Camilla L Nord; Rebecca P Lawson; Tim Dalgleish
Journal:  Am J Psychiatry       Date:  2021-06-22       Impact factor: 19.242

View more
  2 in total

1.  Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.

Authors:  Sahib S Khalsa; Teresa A Victor; Rayus Kuplicki; Hung-Wen Yeh; Kimberly E Vanover; Martin P Paulus; Robert E Davis
Journal:  Neuropsychopharmacology       Date:  2022-04-29       Impact factor: 8.294

2.  A single oral dose of citalopram increases interoceptive insight in healthy volunteers.

Authors:  James J A Livermore; Clare L Holmes; Gyorgy Moga; Kristian Adamatzky; Hugo D Critchley; Sarah N Garfinkel; Daniel Campbell-Meiklejohn
Journal:  Psychopharmacology (Berl)       Date:  2022-03-24       Impact factor: 4.415

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.